Recent Updates
Recently added Catalysts

V205C, measles, mumps, and rubella virus vaccine live

Phase 2

Measles | Monoclonal antibody | Infectious Disease |Merck & Company, Inc.|Last Updated: Mar 15, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment1,100

FDA Designations

No designations recorded

Clinical trial landscape

V205C, measles, mumps, and rubella virus vaccine live · 1 trial · 1 indication

Phase 2 1
NCT00109278A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)Measles
COMPLETED1,100 Analytics
PHASE2COMPLETED
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
Measles
NCT001092781,100
Unlock trial analytics

Study Endpoints

Primary Endpoints

Antibody response rate to measles at 6 weeks postvaccination

Secondary Endpoints

Geometric mean titers to measles by ELISA at 6 weeks postvaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION

Interventions

NameTypeDescription
V205C, measles, mumps, and rubella virus vaccine liveBIOLOGICAL -
Comparator: Measles, Mumps, and Rubella Virus Vaccine LiveBIOLOGICAL -
Unlock Study Design Details

Eligibility Criteria

Age Range12 Months to 18 Months
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Healthy children 12 to 18 months of age. Exclusion Criteria: * Previous receipt of measles, mumps, rubella and/or varicella vaccine. * Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster. * Any medical condition that might in...

Unlock Eligibility Criteria